DnB Asset Management
AXSM icon

DnB Asset Management’s Axsome Therapeutics AXSM Stock Holding History

DnB Asset Management’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$16M Sell
65,199
-24,889
-28% -$5.4M 0.04% 267
2026
Q1 		$15.2M Sell
90,088
-11,014
-11% -$1.9M 0.05% 235
2025
Q4 		$18.5M Sell
101,102
-879
-0.9% -$123K 0.06% 193
2025
Q3 		$12.4M Buy
101,981
+25,339
+33% +$2.85M 0.05% 256
2025
Q2 		$8M Buy
76,642
+15,114
+25% +$1.6M 0.03% 301
2025
Q1 		$7.18M Sell
61,528
-12,242
-17% -$1.39M 0.03% 312
2024
Q4 		$6.24M Buy
73,770
+67,626
+1,101% +$6.22M 0.03% 345
2024
Q3 		$552K Buy
6,144
+72
+1% +$6.29K ﹤0.01% 657
2024
Q2 		$489K Buy
6,072
+1,646
+37% +$122K ﹤0.01% 653
2024
Q1 		$353K Buy
+4,426
New +$371K ﹤0.01% 670

Other funds holding AXSM

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $4.25B AUM 141.71% 1-Year Est. Return

DnB Asset Management's AXSM Position: Q2 2026 in Review

DnB Asset Management reduced its Axsome Therapeutics (AXSM) stake by 28% in Q2 2026, selling an estimated $5.4M and leaving 65,199 shares worth $16M. The position accounts for 0.04% of the portfolio, ranked #267.

DnB Asset Management first reported a position in AXSM in Q1 2024 and has held it in 10 quarters since. The position peaked at $18.5M in Q4 2025. 242 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

  • DnB Asset Management held 65,199 shares of Axsome Therapeutics worth $16M as of Q2 2026.
  • DnB Asset Management sold 24,889 Axsome Therapeutics shares in Q2 2026, an estimated $5.4M.
  • Axsome Therapeutics made up 0.04% of DnB Asset Management's portfolio in Q2 2026, its #267 holding.
  • DnB Asset Management first reported a position in Axsome Therapeutics in Q1 2024 and has held it in 10 quarters since.
  • DnB Asset Management's Axsome Therapeutics position peaked at $18.5M in Q4 2025.
  • 242 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on DnB Asset Management's 13F filing for Q2 2026, filed 11 Aug 2026.